Member Info for Laura2022

Yes

Cannacord and Miton both had fund redemption issues

I've added more today

GBP The footprint of the coincident response at Juno is several times larger than the world-class Havieron #Gold-#Copper deposit which illustrates the significant size of the opportunity at Juno

The intensity of the gravity response at Juno is more elevated

My apologies

Sorry

I will ..finally take your advice on this poster

Trout

Bizarre way of looking at things when on other boards you critics the very same type of posters but not Jaari888

Simple

Challenge then report

Info@lse.co.uk

King

Still find it strange only you and I show this liar for what he is ..whereas other "holders" stay silent

And yet again wrong with lies as he has done for 6mths

PYC does have a commercial relationship with NASDAQ listed DoseMeRx

https://www.physiomics.co.uk/physiomics-adds-modeling-and-data-science-functionality-to-dosemes-precision-dosing-platform/

Tricky

This poster is like a deranged stalker

Also..because of low vahs burn relatove to revenues and CEO who don't take advantage with excessive salaries (PYC are 1/4 of AIM average) there are still only 210mlm shares in issue

So relatively low free float

Look at the PYC partnership with NASDAQ listed DoseMeRx

Updated in June 2024

This A.I software tool will be revolutionary and save $$blns

See a post from KingHomer on here

Some A.I stocks which generate little or no revenue are £20-40mlmnca

PYC £1.7mln

Even LUNG is £10mln and had no money or revenues

Aa

SAR and PYC are different companies and different focus

PYC helps companies like SAR in their drug development

Stockraiser

Partic because at £1.6mln cap PYC almost generates the most revenues per market cap across AIM

AND lowest CEO wages on AIM

Jaari888

Posted 20% times (90%) on pyc

Now up 100% since he posted in Nov

Lucky omen

Https://www.physiomics.co.uk/personalised-cancer-treatment/

We have developed a tool to help physicians understand the effect of the drug in specific patients and enable them to see the possible effect of changing dose

Current personalised-dosing tools typically require costly additional assays and do not provide insight into toxicity or efficacy.

Personalised Dosing Tool Development

Data Identification

Identified public domain data on treatment of prostate cancer using docetaxel for 400+ patients from the comparator arm of a clinical trial

AI & Machine Learning

Applied AI techniques such as neural networks and other machine learning approaches to identify key factors linking dose, toxicity and efficacy

Very wrong Jaar

Hitesh works with PYC A.I and various projects and is negative on MS USE of A.I

Nice try

Please could you re posti your summary

See Basil Alderman post on here 2 weeks ago

Not surprised as PYC swimming with the big companies like Astellas $17bln cap

At forefront of A.I drug discovery and only £1.6mln cap with almost £1mln revenues already booked for first 6mths